AIP
TSHA icon

Arrowpoint Investment Partners’s Taysha Gene Therapies TSHA Stock Holding History

Arrowpoint Investment Partners’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,200
Closed -$39.9K – 144
2025
Q3 		$39.9K Buy
+12,200
New +$34.5K 0.04% 75

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowpoint Investment Partners's TSHA Position: Q4 2025 in Review

Arrowpoint Investment Partners sold out of Taysha Gene Therapies (TSHA) in Q4 2025, closing a stake of 12,200 shares — an estimated $39.9K sold.

Arrowpoint Investment Partners first reported a position in TSHA in Q3 2025 and held it in 1 quarter. The position peaked at $39.9K in Q3 2025. 195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

  • Arrowpoint Investment Partners reported no remaining Taysha Gene Therapies position as of Q4 2025 after selling out during the quarter.
  • Arrowpoint Investment Partners sold 12,200 Taysha Gene Therapies shares in Q4 2025, an estimated $39.9K.
  • Arrowpoint Investment Partners first reported a position in Taysha Gene Therapies in Q3 2025 and held it in 1 quarter.
  • Arrowpoint Investment Partners's Taysha Gene Therapies position peaked at $39.9K in Q3 2025.
  • 195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on Arrowpoint Investment Partners's 13F filing for Q4 2025, filed 11 Feb 2026.